{"url_path":"/sec/ensc/8-k/2026-07-15/item-5-02","section_key":"item-5-02","section_title":"Item 5.02 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-15","source_url":"https://www.sec.gov/Archives/edgar/data/1716947/0001493152-26-033360-index.html","accession_number":"0001493152-26-033360","cik":"0001716947","ticker":"ENSC","issuer_name":"Ensysce Biosciences, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1716947/0001493152-26-033360-index.html","primary_entity_key":"0001716947","primary_entity_name":"Ensysce Biosciences, Inc."},"word_count":49,"has_tables":true,"body_markdown":"**Item\n5.02**\n**Departure\nof Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers**\n\n \n\nOn\nJuly 10, 2026, Ensysce Biosciences Inc. (the “Company”) received a resignation notice, dated and effective July 10, 2026,\nfrom Jeffrey Millard, who served as our Chief Operating Officer."}